We are a clinical-stage biotechnology company with a transformative proprietary cell therapy platform with the potential for treating Chronic Kidney Disease using a patient’s own cells.
Our approach seeks to redefine the treatment of Chronic Kidney Disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration or improvement of kidney function to stop or delay progression of CKD. Our lead product candidate, REACT, is designed to stabilize or improve kidney function in a CKD patient’s diseased kidneys. REACT is an investigational cell therapy product that includes selected renal cells (SRCs) prepared from the patient’s renal biopsy tissue. SRCs are formulated into a product for reinjection into the patient’s kidney using a minimally invasive outpatient procedure. Because REACT is a personalized treatment composed of cells prepared from a patient’s own kidney, there is no need for treatment with immunosuppressive therapies, which are required during a patient’s lifetime when a patient receives a kidney transplant from another, allogeneic donor.